- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.
BHC
TOR
Week ended 31 Jul 2026
Weekly Investor Report
Bausch Health Companies Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
9.65 CAD
54.4%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 25.9% above the Trend Line and sits at 60.5% of its 52-week range. The latest completed week returned 54.4%, after a 38.6% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers. The latest news-sentiment score is 56/100.
Setup score
52
out of 100
Latest Close
9.65 CAD
31 Jul 2026
1W Return
54.4%
latest completed week
4W Return
38.6%
short-term follow-through
12W Return
22.5%
quarterly tape
Trend Breadth
40.4%
21 of 52 weeks active
Volume Ratio
3.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Recent volatility is running well above the one-year baseline.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
54.4%
Latest completed week; four-week move 38.6%.
Indicator stack
22/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
56/100
29 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 25.9% above the Trend Line and sits at 60.5% of its 52-week range. The latest completed week returned 54.4%, after a 38.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 3.3x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1112-week average 0.09
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.11Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 38.6% over four weeks, 22.5% over 12 weeks, and 22.3% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year21
Trend breadth40.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.12Latest activity-pressure read.
Pressure change28.0%Four-week change in activity pressure.
Leadership3.81Latest relative-leadership reading.
RS change113.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 79%
Model confidence 76%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength86/100Blend of value, momentum, and quality. Underlying universe rank 15; rank 1 is best.
Value88/100Relative valuation strength. Underlying universe rank 13; rank 1 is best.
Quality97/100Profitability and accounting quality. Underlying universe rank 4; rank 1 is best.
Momentum7/100Medium-term price momentum. Underlying universe rank 94; rank 1 is best.
Growth66/100Revenue and earnings growth. Underlying universe rank 35; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework91/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.2x Market value relative to trailing revenue.
- EV / EBITDA
- 11.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 71.0% Gross profit retained from each unit of revenue.
- Operating margin
- 23.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 9.4% Free cash flow generated from revenue.
- Return on invested capital
- 10.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 6.7% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -21.0% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 10.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment56/100
Weighted news tone is neutral across 29 relevant articles.
6 positive · 23 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-19.4%Distance below the 52-week high.
13-week volatility15.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher15 of 2611 weeks finished lower.
Best week+54.4%Week of 31 Jul.
Worst week-9.4%Week of 6 Mar.
Latest week+54.4%Week of 31 Jul.
Shape of recent returns
Strong gains3
Modest gains12
Flat weeks0
Modest losses4
Sharp losses7
Recent vol15.4%13-week weekly-return volatility.
Base vol11.1%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCA Healthcare
4-week rank1 / 46
Group average-1.8%
Trend breadth37.0%
Trend37.0%active weekly trend signals
MD47.8%positive activity pressure
RS23.9%positive relative leadership
Four-week leaders
IndustryCA Drug Manufacturers - Specialty & Generic
4-week rank1 / 21
Group average-1.4%
Trend breadth42.9%
Trend42.9%active weekly trend signals
MD38.1%positive activity pressure
RS23.8%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape43/100
Trend, activity pressure, participation, and risk combine to a 43/100 tape read.
Indicator analysis21/100Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 1/12.
Activity pressure 0.11; No reversal markers Factors71/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 53; Small Cap Core rank 25 SVQF91/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 26.5 of 298 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment56/100Weighted news tone is neutral across 29 relevant articles.
Bausch Health Stock (BHC) Opinions on Q2 2026 Earnings Results Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 9.65 CAD | 54.4% | 7.67 CAD | 9.52 CAD | -0.12 | 3.81 | 6.9M | Off |
| 24 Jul 2026 | 6.25 CAD | -7.8% | 7.67 CAD | 9.53 CAD | -0.55 | -33.13 | 2.4M | Off |
| 17 Jul 2026 | 6.78 CAD | 0.1% | 7.79 CAD | 9.57 CAD | -0.31 | -28.08 | 2.0M | Off |
| 10 Jul 2026 | 6.77 CAD | -2.7% | 7.88 CAD | 9.61 CAD | -0.26 | -28.91 | 1.8M | Off |
| 3 Jul 2026 | 6.96 CAD | 2.8% | 7.98 CAD | 9.64 CAD | -0.16 | -27.48 | 1.9M | Off |
| 26 Jun 2026 | 6.77 CAD | 3.0% | 8.07 CAD | 9.67 CAD | -0.18 | -29.67 | 1.9M | Off |
| 19 Jun 2026 | 6.57 CAD | -7.3% | 8.14 CAD | 9.69 CAD | -0.12 | -32.37 | 320.3K | Off |
| 12 Jun 2026 | 7.09 CAD | -5.3% | 8.20 CAD | 9.71 CAD | 0.02 | -27.62 | 742.0K | Off |
| 5 Jun 2026 | 7.49 CAD | 1.1% | 8.26 CAD | 9.73 CAD | 0.10 | -22.91 | 539.9K | Off |
| 29 May 2026 | 7.41 CAD | -1.9% | 8.32 CAD | 9.74 CAD | 0.23 | -24.67 | 2.2M | Off |
| 22 May 2026 | 7.55 CAD | 1.1% | 8.40 CAD | 9.76 CAD | 0.28 | -22.71 | 1.8M | Off |
| 15 May 2026 | 7.47 CAD | -5.2% | 8.44 CAD | 9.79 CAD | 0.12 | -22.18 | 2.3M | Off |
| 8 May 2026 | 7.88 CAD | 2.7% | 8.47 CAD | 9.81 CAD | -0.09 | -18.67 | 2.1M | Off |
| 1 May 2026 | 7.67 CAD | -0.3% | 8.50 CAD | 9.81 CAD | -0.43 | -20.51 | 2.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.